<h2 data-section-id="1io9wes" data-start="0" data-end="25"><strong>IgA Nephropathy Market</strong></h2>
<p data-start="27" data-end="754">The <a href="https://www.delveinsight.com/report-store/iga-nephropathy-igan-market"><strong>IgA Nephropathy (IgAN) market</strong></a> is witnessing rapid transformation with the introduction of targeted and disease-modifying therapies. The 7MM market size reached nearly USD 1.5 billion in 2025 and is projected to grow at a CAGR of 18.6% during 2026-2036. The United States accounted for approximately 80% of the total market share in 2025, driven by higher diagnosis rates and faster adoption of innovative therapies. The market is gradually shifting from supportive care toward precision-based treatment approaches targeting APRIL/BAFF pathways, complement activation, and immune modulation. Increasing physician awareness, regulatory approvals, and pipeline advancements are expected to further strengthen market expansion.</p>
<h3 data-start="756" data-end="781"><strong data-start="756" data-end="781">Key Market Highlights</strong></h3>
<ul data-start="782" data-end="1050">
<li data-section-id="1y0f9d7" data-start="782" data-end="833">7MM market size reached USD 1.5 billion in 2025</li>
<li data-section-id="1gidz20" data-start="834" data-end="875">Expected CAGR of 18.6% from 2026-2036</li>
<li data-section-id="1k2ujyw" data-start="876" data-end="925">US contributed nearly 80% of the market share</li>
<li data-section-id="13jdxjs" data-start="926" data-end="985">Rising adoption of targeted therapies is driving growth</li>
<li data-section-id="t9jssi" data-start="986" data-end="1050">Strong pipeline expected to improve long-term renal outcomes</li>
</ul>
<h3 data-start="1052" data-end="1070"><strong data-start="1052" data-end="1070">Approved Drugs</strong></h3>
<ul data-start="1071" data-end="1342">
<li data-section-id="pq8x9z" data-start="1071" data-end="1171"><span class="whitespace-normal">Asahi Kasei</span> / <span class="whitespace-normal">Calliditas Therapeutics</span> - <a href="https://www.delveinsight.com/report-store/tarpeyo-market-drug-insight-and-market-forecast"><strong>TARPEYO</strong></a>/KINPEYGO</li>
<li data-section-id="1okc57g" data-start="1172" data-end="1224"><span class="whitespace-normal">Travere Therapeutics</span> - <a href="https://www.delveinsight.com/report-store/filspari-drug-insight-and-market-forecast"><strong>FILSPARI</strong></a></li>
<li data-section-id="1evxjgc" data-start="1225" data-end="1290"><span class="whitespace-normal">Novartis</span> - <a href="https://www.delveinsight.com/report-store/fabhalta-drug-insight-and-market-forecast"><strong>FABHALTA</strong></a> and VANRAFIA</li>
<li data-section-id="4wzfbc" data-start="1291" data-end="1342"><span class="whitespace-normal">Otsuka Pharmaceutical</span> - VOYXACT</li>
</ul>
<h2 data-section-id="wqa98b" data-start="1349" data-end="1380"><strong>IgA Nephropathy Epidemiology</strong></h2>
<p data-start="1382" data-end="2043"><a href="https://www.delveinsight.com/report-store/iga-nephropathy-epidemiology-forecast"><strong>IgA Nephropathy</strong></a> is one of the most common primary glomerular diseases worldwide and is more frequently observed in Asian populations compared to Western countries. In 2025, the diagnosed prevalent cases across the 7MM were estimated at nearly 415K cases. Japan represented the highest share with 42% of total diagnosed cases, followed by the US with 33% and EU4 plus the UK with 25%. The disease often remains asymptomatic for years, leading to delayed diagnosis and disease progression. Approximately half of patients continue to experience proteinuria above the target threshold, increasing the risk of chronic kidney disease progression and renal impairment.</p>
<h3 data-start="2045" data-end="2074"><strong data-start="2045" data-end="2074">Epidemiology Segmentation</strong></h3>
<ul data-start="2075" data-end="2233">
<li data-section-id="e6e93y" data-start="2075" data-end="2118">Total diagnosed prevalent cases of IgAN</li>
<li data-section-id="1cyfy11" data-start="2119" data-end="2154">Gender-specific diagnosed cases</li>
<li data-section-id="1a2ipzt" data-start="2155" data-end="2187">Age-specific diagnosed cases</li>
<li data-section-id="14peoaq" data-start="2188" data-end="2233">Region-wise disease burden across the 7MM</li>
</ul>
<h3 data-start="2235" data-end="2264"><strong data-start="2235" data-end="2264">Key Epidemiology Insights</strong></h3>
<ul data-start="2265" data-end="2536">
<li data-section-id="1kyet8h" data-start="2265" data-end="2322">Diagnosed prevalent cases in 7MM reached 415K in 2025</li>
<li data-section-id="1fofvxk" data-start="2323" data-end="2365">Japan accounted for 42% of total cases</li>
<li data-section-id="lly2f4" data-start="2366" data-end="2407">US represented 33% of diagnosed cases</li>
<li data-section-id="3psfkz" data-start="2408" data-end="2451">EU4 and the UK contributed 25% of cases</li>
<li data-section-id="1rd0bqn" data-start="2452" data-end="2536">Asian populations show higher disease prevalence compared to Western populations</li>
</ul>
<h2 data-section-id="bx08ya" data-start="2543" data-end="2570"><strong>IgA Nephropathy Pipeline</strong></h2>
<p data-start="2572" data-end="3279">The <a href="https://www.delveinsight.com/report-store/iga-nephropathy-igan-pipeline-insight"><strong>IgA Nephropathy pipeline</strong></a> is highly competitive and focused on disease-modifying strategies aimed at reducing immune-mediated kidney damage. Several companies are developing innovative therapies targeting APRIL/BAFF signaling, complement pathways, and plasma cell activity. Emerging therapies are expected to improve proteinuria control, delay kidney function decline, and provide safer long-term treatment alternatives. Among pipeline candidates, ALPN-303 (<a href="https://www.delveinsight.com/report-store/povetacicept-market-size-forecast-and-emerging-insight"><strong>Povetacicept</strong></a>) is projected to generate the highest revenue in the 7MM by 2036. The growing emphasis on precision medicine and targeted immunological approaches is expected to redefine the future treatment landscape of IgAN over the coming decade.</p>
<h3 data-start="3281" data-end="3304"><strong data-start="3281" data-end="3304">Key Pipeline Trends</strong></h3>
<ul data-start="3305" data-end="3544">
<li data-section-id="hkpknr" data-start="3305" data-end="3347">Focus on<a href="https://www.delveinsight.com/report-store/baff-and-april-targeted-therapies-market-forecast"> APRIL/BAFF</a>-targeted therapies</li>
<li data-section-id="1es8atr" data-start="3348" data-end="3388">Development of complement inhibitors</li>
<li data-section-id="5c1266" data-start="3389" data-end="3435">Increasing interest in <a href="https://www.delveinsight.com/report-store/anti-cd38-antibody-pipeline-insight"><strong>anti-CD38 therapies</strong></a></li>
<li data-section-id="pnf3c6" data-start="3436" data-end="3491">Shift toward disease-modifying treatment approaches</li>
<li data-section-id="1yws8ep" data-start="3492" data-end="3544">Strong clinical research activity across the 7MM</li>
</ul>
<h3 data-start="3546" data-end="3563"><strong data-start="3546" data-end="3563">Key Companies</strong></h3>
<ul data-start="3564" data-end="3841" data-is-last-node="" data-is-only-node="">
<li data-section-id="hjs5dh" data-start="3564" data-end="3605"><span class="whitespace-normal">Travere Therapeutics</span></li>
<li data-section-id="pzvh1x" data-start="3606" data-end="3647"><span class="whitespace-normal">Novartis</span></li>
<li data-section-id="1l5awad" data-start="3648" data-end="3689"><span class="whitespace-normal">Asahi Kasei</span></li>
<li data-section-id="1upsd79" data-start="3690" data-end="3731"><span class="whitespace-normal">Calliditas Therapeutics</span></li>
<li data-section-id="1xaspf9" data-start="3732" data-end="3773"><span class="whitespace-normal">Biogen</span></li>
<li data-section-id="8hqlpy" data-start="3774" data-end="3841" data-is-last-node=""><span class="whitespace-normal">AstraZeneca</span> / Alexion Pharmaceuticals</li>
</ul>

IgA Nephropathy Market Insights